Melanotan II's published controlled trials enrolled 23 men, the last in 2000. An FDA panel is due to consider it by February 2027.

Why this note exists

Advisory-committee scheduling tends to be read as momentum. FDA's early announcement, current as of April 15, 2026, lists cathelicidin (LL-37), GHK-Cu, dihexa acetate, Melanotan II and pegylated mechano growth factor, and says FDA "intends to publish a Federal Register notice and establish a docket for public comment on this meeting in the near future."[1] A Federal Register search on September 19, 2026 for "Pharmacy Compounding Advisory Committee" returned no notice for that meeting, and a search for "melanotan" returned a single document, a 2016 debarment order discussed below.[20] The meeting date and the briefing documents are therefore not public yet.

This note sets out what the panel will have to work with: the regulatory record as FDA currently states it, every published controlled human study pepmg could find, the approved molecule that differs from Melanotan II at one end, and the uncontrolled safety literature. A note on evidence types: each human figure carries its design and participant count, case reports are called case reports in the same sentence, and label data about bremelanotide are identified as data about bremelanotide.

The regulatory record

Not approved, not on any 503A category, and already carrying an FDA safety entry

An openFDA query of Drugs@FDA data on September 19, 2026 returned no application with melanotan as an active ingredient.[21] On compounding, FDA's running list of substances nominated under section 503A, updated May 14, 2026, sorts nominations into category 1 (under evaluation), category 2 (significant safety risks) and category 3 (nominated without adequate support). Melanotan II appears in none of the three.[3]

It appears on a different page. FDA's list of bulk drug substances that may present significant safety risks, current as of April 22, 2026, places it under "[b]ulk drug substances nominated but withdrawn," a section that FDA describes as substances "previously in category 2 of the interim policies [that] were withdrawn by the nominators."[2] The entry reads in full: "Compounded drugs containing Melanotan II may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities. Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism."[2]

FDA's view that Melanotan II is an unapproved new drug is on the record from well before this cycle. A 2016 debarment order in the Federal Register recounts that in August 2007 FDA sent a warning letter to a company advertising Melanotan II as an injectable tanning product, stating that it "constituted a new drug under the FD&C Act that could not be introduced or delivered for introduction into interstate commerce without an FDA approved application."[24] The order records that the company's owner was later convicted of federal felonies, including conspiring to defraud the United States by shipping the product to US customers after telling FDA the company would not, and that FDA permanently debarred him.[24]

What a panel meeting can and cannot do matters here. FDA's own description is that "[a]dvisory committees make nonbinding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so."[4] A 503A bulks-list vote is also a different question from approval: it concerns whether pharmacies may compound with a nominated bulk substance, not whether a medicine has shown it is safe and effective.[3][4] Melanotan II was not among the seven substances discussed at the July 23–24, 2026 meeting.[5]

The human evidence

Three controlled studies, one lab, all men

A PubMed search on September 19, 2026 for Melanotan II restricted to the clinical trial publication type returned four records.[19] Three are primary studies and the fourth is the same investigators' review of two of them.[9]

Figures as reported in each paper's abstract. All three studies come from the University of Arizona group that developed the compound.[6][7][8]

The 1996 pilot is the only one that looked at skin. Three healthy men received subcutaneous Melanotan II or saline on alternating weekdays for two weeks, starting at 0.01 mg/kg; two were escalated to 0.03 mg/kg and one to 0.025 mg/kg.[6] The authors report that "[t]wo subjects had increased pigmentation in the face, upper body and buttock, as measured by quantitative reflectance and by visual perception 1 week after MT-II dosing ended," and that 0.03 mg/kg "produced Grade II somnolence and fatigue in one of two subjects."[6] They also noted spontaneous erections for one to five hours after dosing. That is the entire controlled human evidence on tanning: two men, one week after five doses.[6]

The two trials that followed moved to erectile dysfunction. In 1998, ten men with no known organic cause received Melanotan II and vehicle in a double-blind crossover, with erections monitored by RigiScan for six hours; eight of ten developed clinically apparent erections, with a mean duration of tip rigidity above 80% of 38.0 minutes against 3.0 on placebo (p = 0.0045).[7] In 2000, ten men with organic risk factors received 0.025 mg/kg subcutaneously and vehicle, each twice; injections of Melanotan II produced subjectively reported erections in 12 of 19 cases against 1 of 21 placebo doses, and mean tip rigidity above 80% lasted 45.3 minutes against 1.9 (p = 0.047).[8]

The side effects were consistent across all three. Nausea and a stretching-and-yawning complex recur in each abstract; the 2000 trial recorded severe nausea after 4 of 19 injections, and the group's review of both trials reports that at 0.025 mg/kg "12.9% of subjects had severe nausea."[8][9] The 1998 authors described the side effects as transient and said none required treatment.[7]

Those doses are reported here as the papers published them, per kilogram, in men, in single or short-course use. pepmg does not convert a per-kilogram research dose into an amount, and none of these studies ran long enough to say anything about repeated use over a season.

The approved relative

Bremelanotide differs at one end, and its label records the pigment effect

The 1996 paper gives Melanotan II's structure as "Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10 alpha-MSH4-10-NH2," a lactam-bridged cyclic heptapeptide.[6] The prescribing information for Vyleesi describes bremelanotide as "a synthetic, cyclic heptapeptide with a free acid at the carboxyl terminus," structure "Ac-Nle-cyclo-(Asp-His-D-Phe-Arg-Trp-Lys-OH)."[10] Same residues, same ring; the published difference is an amide versus a free acid at the carboxyl end. That is still a different molecule, and nothing on the Vyleesi label is data about Melanotan II. pepmg covers it separately as PT-141 .

Bremelanotide went through phase 3 trials and FDA review. FDA approved it on June 21, 2019 under NDA 210557, and the label restricts it to premenopausal women with acquired, generalized hypoactive sexual desire disorder, "not indicated for the treatment of HSDD in postmenopausal women or in men" and "not indicated to enhance sexual performance."[11][10] The approved regimen is 1.75 mg by autoinjector as needed, no more than one dose in 24 hours, with more than eight doses a month not recommended.[10]

The label's pigment warning is the closest controlled evidence that exists for what the Melanotan II market is using. In the phase 3 placebo-controlled trials, focal hyperpigmentation "including involvement of the face, gingiva, and breasts" was reported in 1% of patients on up to eight doses a month, against none on placebo. In another study, 38% developed focal hyperpigmentation after daily dosing for 8 days, and among those who continued for 8 more days, an additional 14% developed new changes. Patients with dark skin were more likely to be affected, and resolution "was not confirmed in all patients after discontinuation."[10] The label also records transient blood-pressure rises of up to 6 mmHg systolic and 3 mmHg diastolic after each dose, and nausea in 40% of patients in the phase 3 trials.[10] Again: those are bremelanotide figures, from a regulated product at a labeled dose.

Outside the trials

Case reports, and what testing of sold vials found

Most of what is known about Melanotan II in wider use comes from case reports, which record that something happened to one person and cannot establish incidence or cause. The most cited review, in the International Journal of Dermatology in 2017, found that case reports associate unregulated melanotan I and II use with "melanocytic changes in existing moles and newly emerging (dysplastic) nevi," that four reports described melanomas emerging from existing moles during or shortly after use, and that "conclusive evidence linking these phenomena is lacking."[13]

Individual reports since then include two cases of ischemic priapism after melanotan injection, one managed without surgery but without recovery of erectile function at four weeks and one needing surgical decompression; a renal infarction its authors judged "most likely attributed to Melanotan II"; and a mucosal malignant melanoma of the anterior maxilla in a 22-year-old woman who had used a Melanotan II nasal spray, reported as a "possible risk factor."[15][14][16][17] Each is one patient. FDA's entry names melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism from the same kind of literature, and none of it establishes how often those events occur.[2]

Product quality is the second gap FDA's entry points at. A 2015 study bought Melanotan II vials labeled 10 mg from three online shops; measured content ranged from 4.32 to 8.84 mg, and vials from two shops contained unknown impurities of 4.1% to 5.9%.[18] A Belgian forensic laboratory that was sent a vial labeled Melanotan II for identification reported in 2024 that its contents were 30% pure.[12] Those are small samples from specific sources and years; they do not describe any vendor pepmg tracks, and pepmg makes no claim about the contents of any vial.

What is running now

One registered trial, and a thin record

ClinicalTrials.gov returned a single study for "melanotan" on September 19, 2026.[22] NCT07437560 is registered by Hudson Biotech as a randomized, placebo-controlled, quadruple-masked phase 2 study of Melanotan II added to narrowband UVB phototherapy in adults with stable nonsegmental vitiligo, with an estimated enrollment of 60, one site in Shenzhen, China, and a primary outcome of change in Vitiligo Area Scoring Index at 24 weeks.[23]

The record lists the study as recruiting, with an actual start date of February 2, 2026, but it has not been updated since it was first posted on February 27, 2026, and it describes the intervention only as "administered per protocol," with no dose, route or frequency.[23] No results are posted, and the estimated primary completion date is February 14, 2027.[23] A vitiligo result, when it comes, would be evidence about repigmentation alongside phototherapy, not about cosmetic tanning.

Three things this note is not saying

It is not predicting the panel's vote. FDA has not published the briefing documents, the nominated uses or a meeting date, and a recommendation either way would be nonbinding.[1][4]

It is not saying Melanotan II does nothing. In small controlled studies it produced erections against placebo, and in a three-man pilot it darkened skin; the melanocortin pharmacology is real and a near-identical molecule is an approved drug.[6][7][8][10]

It is not saying Melanotan II causes melanoma. The review that gathered the reports calls the evidence inconclusive.[13] What it is saying is that the controlled human record is 23 men in three short studies from one lab, the last published in 2000, and that is what a February 2027 panel would be weighing.

Questions people are asking